HUE030210T2 - Módszerek az IL-21 alkalmazására adoptív immunterápia és tumor antigének azonosítása céljából - Google Patents

Módszerek az IL-21 alkalmazására adoptív immunterápia és tumor antigének azonosítása céljából Download PDF

Info

Publication number
HUE030210T2
HUE030210T2 HUE05852204A HUE05852204A HUE030210T2 HU E030210 T2 HUE030210 T2 HU E030210T2 HU E05852204 A HUE05852204 A HU E05852204A HU E05852204 A HUE05852204 A HU E05852204A HU E030210 T2 HUE030210 T2 HU E030210T2
Authority
HU
Hungary
Prior art keywords
cells
tumor
további
antigen
cell
Prior art date
Application number
HUE05852204A
Other languages
English (en)
Inventor
Cassian Yee
Original Assignee
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res filed Critical Hutchinson Fred Cancer Res
Publication of HUE030210T2 publication Critical patent/HUE030210T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (4)

  1. MfoSSSttKAZ IL-21 ALKALMAZÁSÁRA ABOrrW IIM!NIIlál>Iá ÉS TtWM ANTIC tíiSK AZONOS í'TÁSA CÉIJÁBÓL SzíSMíIsMA %áoyp«stefe: í< í|%írio¥sní%®a asmwsMsái'a s2B|g&amp;iÓ·raéósge% aspely áékiábbi íápésbkböi áMí. az alanyból teoláb teíbi'xtteysg bg^BSSiíayfeSxffcsí? perifériás vÉfsejtekkel fFBMO# agy !i,L'-2l terialyte késxiteylpy # ·:^Β^ίίψί«^]ί|.!0 «<^|ek·: (ÁBC-k) jsteólátebety C'XíS* ΐΑ^ΐ .:popaí8«:lB:|p>!Ak &amp; tei^yószeíMk ## ág éíbáííteAf: ^0*sot%#jaNsj>«ciStor3^^:«MTO-:2W^·· msr a^gbsMsya az ÍD4I iásp!!sNl«« tmϊλοίδϊΐtigési'·sfp«5Cí fiks.s s i-efe ssgmst, egyeds CpS*· ^sejtek kliteóéásá ..¾ CP#- T->seíkpo»»láelbbdli és, azamigéti szonoxíláss aT···;# klóaük atitjgémspecülejtásának teirása kijárt. :S, Az Ϊ i$énipin%:8$%É&amp;Ü m&amp;fe:ter,:&amp;lte] a .£$3$·*· Tteéít pöpöjfeíói&amp;iCBiSSA, ég képes ÍL-2 eíósliliására,
  2. 3, Az '·. igénypiíiU ;i CMP^Ifkseji populáció;mmtetí»méis&amp;»;<!ií(fw»sjá!iiCDSM· T·*# popeláció.
  3. 4, - Ax i. igénypom föéíimi ybódszek áh$,&amp;^BMC vagy ClMk T-sífi gopAsié egy au-ológ sejtpopuláció. f, -Az. A Igéísypdöf m$&amp;€fé#«r,::ást;limmmy’&amp;g teíJ«s--il^%iMji. temmsejteker vagy gpoptódkits testeket tartalmaz. $< Az $J0sypm ^&amp;mö méSmm *b«I h <m vágy #11 tövlbbi föd:ö]da: jéléBfötóbSÍV O AésBc, ?, AíkgíSív imnnmtmpiáfegn m» hamtM&amp;m szolgáló, toogaJMjges^speelBksé CDS·;· ImmáP lAifi -populáció készítésének módszere, onsly az alábbi iepesesboí alk perifériái. vér xíionoHiAíaéris sebek (FBMCék) izolálása egy biológiai mlsíáhók ahol az említeti PBMCék egy tes# CDfó lom# T~s«j*jpopöláe» képeznék; olyan FBMC-k axonosiiss, mélyek iénteipím Íósxtek>mpai)bilií a daganatban szenvedd alannyal; aaiv CDS; barnán 1#«# populáció izolálása az emliisli hisxmkinnjBtibdte bBMC-kból; ax alanyból izolált tmnomnysg és naiv CDID immáxt T-sejt populáció :Ígyüts--tenyésxféxe iLOBt tartalmazó készítmény és öniigéüpmxamzló sebek (APCAs jelenlétében, almi az említett mmomoyag egy ixmummiigém. tariaimax; és a sejtek szaporltásá teítyöszobea, ahol az :g|i5ó1«toB:^m^»%^#^llfe-'CÖ8#'bU}öáö: t-sejtek szánta 20-30tezor nagyobb, ííéíí: ax Π..-2Ι tevollétébest előállított tus«oramlgétKspeciíík»s CD8-t-bmnáa Tömitek száma- 4«, A χφ\γρ*Μ sesrntöi eAdsZéh ahol &amp; &amp;KmwaaUgjíMp^fí&amp;W £$>^,k88»» l -seítpc^ulaeié G£M$H\, ás képes II C. előállításra. %. A % jgónpont sgexlnb mé<ta^ JühöJ s PSbfGk: suiolögbis. Λ AxíeptíV imíísíísteij-sgisbas: vált ftassngMía sgxiígálö:> í^5|'·' humán íxsp-iiádó készítőéinek .módszere, amely a» alábbi lépésekből áll: T-ssyefcet taxtebnasó xaxiáli humán biológiai mintából:; naiv 0?8·ϊ· huxn.án T-uejt populáció izolálása az enűimíbkte: t ••s^ixipoláéióbói: a* alanyból sxáimasS intnoxauyag és naiv CDő hntaán T~seg populáció pgyött'sesyésgíáse IL-ÍU-í tartalmazó készfenány és APG-k jelasilélóben, ahol az évűikéit tumor anyag W íumofaatÍgáxíi: tax-laknaz; és epeitek sznpontésa tmyésmtöm, &amp;hel m.&amp;MíUtvü tememitigé8*we$ifite»s h8má&amp;"T~s$fá% szánta 29~3Ö-szöf nagyobb, mini az 11.-2! lávoliéíébsn előállított tenwrsmsgen-'SpeciPkns: ÜDE ;· humáti T-sejtek sztes; 1 L A 10, igénypoarszeriuíkmodszer, ;űsol a tamommigés-speoxíxkíxs ö>b5' komán T-u-ep populáció C.D28V, és képei. ÍL-2 előállítására; ti. A 10, igénypont Uérinií aióésmiMiil $€M-r T~s0papéMé sut®í%· 13. A ?. vagy a 10. igénypont sxmsöh módszer, alsó; a íumoxanytig teljen .RNS···. feU; titmaraejteka'. vagy «tpoptónkxts testeket tartalma? 14« A tsáhóxassíigöxí-apecxSkus CD8Á8«mitiiiksejtpop«4Sci4 ex ?iv® szolgáló módszer. ameiy a® alábbi iépésckhöí áll: a d&amp;g&amp;u&amp;tbtm szenveM alatmyal b:isgtepmp.«jbíikip^ égy T-seí-eket tmáínmS izolált humán biológiai ix-iutábót; xaiv CDIte· hunián T-seji populs-bő Izolálása az emlikat hlsztekoxupatibifis humán T-sert populációba;; az alanyból szhm<tzó íutaíimsyag ós egybíHényésídése !i.-21-t tartalmazó készítmény és A.PC-k jslsxiiétéhsn, ahol ág emlt-ett tumor anyag egy iuxmmumgmsí tartalmaz: én a ssytbiAKapfíiiása téxgslszeíbek, aholsz bÍMJHibÖi iumotmtígéú^p<'dfikit' í>um c>u>^íld^:'GÍ>|t· iÖ-vMkszbr xtagyobh, mint m Jíó&amp;i tílyebétébéti elóáíbiott nuno?aihigéiushéé^i«^ humán citotexxfcu·; CIÜS* T-sepes: száma. 15. A 14. igéövposí pgfisih Ípáih:£<í··, ahé! ;s texáa'AkAsikSísClblH' T-seg píypxssásíXSJaAÖkaA US ksípsíS**'"»" alMllMsáxxs. Jé, A 7>, iö. vagy j4:Ag«éyi>víPéiSsenxiíl sióás$vs;\ stó| a :#:í8..C<fM»?' .aytPSH -"é"g poputav-W &amp;gyM4my&amp;Mé&amp;éh&amp;l álló lépési: k&amp;v^:ömif0Íáő8y1^ÉJ' husiik? ciíhíöxikas CD&amp;* Iksujíek.
  4. 17. A sxuporíSölt tiknxíraíiilgén^spöhiítfei-S. C15S·?· Mx;xásx I !}*&amp;&amp;$$}$&amp; :Ü: ISÍíiUxhUh szsSAasló^ alany vég/eU adopíív ííiüxiurjteiiipiáía $.»>ígái<· gys>gysxei- gvánásasa. ahol a xixsKB'anixgvB'Spuviiskks il-'B · Ujiísiáp: fχ$*|ρ·;&amp;:f<$bí|pysia Ílis2Íti^m»^tlfeiifs:^-aSa«yiyal ák-stbóli &amp; :UjyK?3'SötígsS''SpeUsAlk?s l,Dé'í' f AújSékfölíllAll és APíAk jfeatötébös agyiéi íeísy#sís«:élí aé;alásyéol sMsxBxáp taőlepnyaggal*φοΗ· ikííxíöfaíuigéfi- spííiíifik-s'i 0)8·»· h»maa Γ-scjt popsi kteisS a CD2&amp;·*, és képes Il-Al- «l§8l-rf^sát*g .8« -ihöl épsllígli CSlébA, ll:..->2- ?U!:piSl|k p:pppjajs?lgésir-spgSÍl!k5is Cl>§s Ixtixsi&amp;si Hsa-t ixxpaláésöj tsivabfes sstsikáKk i&amp;voHétéfeen ussxyéssisk, aaáls&amp;i sxaixjnt-va: sss-eaj.Uieg-'^Köyaöttg&amp;R'^^íMí^stiöS^ áasm&amp;a 1 -ssíjiukfti 18, iSzsporsíPit CÖ2sM·, R. -2-s-oíms?AÖ. ns-rsi::ras:%é>vsp«díxfc\ss €ΪΜ* hxiixsh; i'· sebek. sxeiyekcs a;·: aissiybol Isöíák ppXKífiüxy&amp;g és psírsisbéás vés' jixsssxiiusklöáxis -íejfek: í'FBMC-k) 11,-21 l&amp;ssssl:xsö sxsssiiméoy és ösAsgéíipsxísessslíé su|tsk (AFC-k) jeiesáaáhsi5 v%sssl:t^ egyölsAsavéssiéss étíáa készítetlek 8 0328^,11^2 eWÉftftsit» kép8Sj.teor^i%4«-^lto bussás; T-ssyt .populáció eföáíbtás&amp; esspbóL és további sCitcÉinefe tévsiÜébíte testvégnek: a ssssriotban szenvedő «Anyaid végzési adopiiv amnmriieíápiábas iíSsxéssb alfesskssszás séliára, W,ABz*mimt msszrmi^stmmmm OG«* *«κ^» '*«&amp;*· a UmmBm rnm^m ém?mI végzett: s«3ístast:terapi;ib;a:s törtéaó alkaissuszás ¢0¾¾¾. -3^ 8 tussorsa'Mgg^spcciílkus ί,178χ· immau i~sejtass fmotipum Ji&amp;xttíkompaí íbíBs; m·. akssHsyak «* ^oi 8 €» teán T*s«jfctok 11-21 és APC-k jd«»tótóben sgYÖÖ ésaxyésabíiték az alanyból száxxts&amp;zsS nsxsso-sssxyagg&amp;k a« a türaoraniígér,-;sps-x'.kik?ss CD 8 ·* · bsixeáss T--sv'íl pöpxsláfcíó a· C .ΆΑ*', >--s kv.sx.·» IL-2 eSoálhSxssAsss, és ssbxb az ásxnivt: <.,Llc.fti, riWtara»»» tumorauligéa-spccito d#* T"S!^ W&amp;tbt feAI ciA>kto«k távoMíébea íiísxyésxílk, esáÍM ssssporiA» az
HUE05852204A 2004-11-24 2005-11-23 Módszerek az IL-21 alkalmazására adoptív immunterápia és tumor antigének azonosítása céljából HUE030210T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63072704P 2004-11-24 2004-11-24

Publications (1)

Publication Number Publication Date
HUE030210T2 true HUE030210T2 (hu) 2017-04-28

Family

ID=36588349

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE05852204A HUE030210T2 (hu) 2004-11-24 2005-11-23 Módszerek az IL-21 alkalmazására adoptív immunterápia és tumor antigének azonosítása céljából

Country Status (12)

Country Link
US (5) US20060269973A1 (hu)
EP (1) EP1814580B1 (hu)
JP (1) JP2008521406A (hu)
CA (1) CA2587136A1 (hu)
CY (1) CY1122390T1 (hu)
DK (1) DK1814580T3 (hu)
ES (1) ES2601896T3 (hu)
HU (1) HUE030210T2 (hu)
LT (1) LT1814580T (hu)
PL (1) PL1814580T3 (hu)
PT (1) PT1814580T (hu)
WO (1) WO2006065495A2 (hu)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
BRPI0511187A (pt) * 2004-05-20 2007-12-04 Zymogenetics Inc método para tratar cáncer em um indivìduo
EP1814580B1 (en) 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
US20080131415A1 (en) * 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
EP1932537A1 (en) * 2006-12-12 2008-06-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Expression of transgenic T cell receptors in LAK-T cells
CN101743249B (zh) 2007-05-11 2017-08-08 阿尔托生物科学有限公司 融合分子与il‑15变异体
WO2009045308A2 (en) 2007-10-03 2009-04-09 Fred Hutchinson Cancer Research Center Enhanced generation of cytotoxic t-lymphocytes by il-21 mediated foxp3 suppression
US9738872B2 (en) 2008-10-30 2017-08-22 Yeda Research And Development Co. Ltd. Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
DK2352756T3 (da) 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen Højaffin T-cellereceptor og anvendelse af denne
CN101824400B (zh) 2009-03-05 2012-08-08 中国科学院微生物研究所 一种放大增殖抗原特异性t细胞的方法
CN103282047B (zh) 2010-09-08 2016-08-24 耶达研究及发展有限公司 抗第三方中枢记忆性t细胞在抗白血病/淋巴瘤治疗中的用途
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
US8507222B2 (en) 2010-09-21 2013-08-13 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
JP2014511704A (ja) 2011-04-13 2014-05-19 イミュニカム・エイビイ Ｔ細胞のプライミングのための方法
CN103502439B (zh) * 2011-04-13 2016-10-12 因缪尼卡姆股份公司 用于抗原特异性t细胞增殖的方法
WO2013013187A1 (en) 2011-07-21 2013-01-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Apolipoprotein e polypeptides and their use
WO2013035099A1 (en) * 2011-09-08 2013-03-14 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
JP2017507950A (ja) * 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
KR102762243B1 (ko) 2014-06-30 2025-02-05 알토 바이오사이언스 엘엘씨 Il-15-베이즈드 분자 및 이의 사용 방법
BR112017005631A2 (pt) 2014-09-19 2018-06-26 City Of Hope células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2
KR20230145241A (ko) 2014-10-01 2023-10-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신
JP6599450B2 (ja) 2014-10-02 2019-10-30 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
US10421751B2 (en) 2015-05-05 2019-09-24 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
AU2016276947A1 (en) 2015-06-11 2017-12-14 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
EP4286511A3 (en) * 2015-06-12 2024-03-06 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
EP3322424B1 (en) 2015-07-16 2023-10-11 Yeda Research and Development Co., Ltd. Use of anti third party central memory t cells
JP2018532729A (ja) * 2015-09-25 2018-11-08 アルター・バイオサイエンス・コーポレーション インターロイキン−１５スーパーアゴニストは、移植片対腫瘍活性を大幅に増強する
SG11201811408PA (en) 2016-06-24 2019-01-30 Univ Mcmaster Adoptive cell transfer and oncolytic virus combination therapy
EP3497243A4 (en) * 2016-08-10 2020-04-01 Aurelius Biotherapeutics, LLC CELL THERAPY COMPOSITIONS AND METHOD FOR USE THEREOF
EP4613776A3 (en) 2016-10-21 2025-11-26 Altor BioScience Corporation Multimeric il-15-based molecules
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
ES3064681T3 (en) 2017-01-18 2026-04-28 Yeda Res And Development Co Ltd Genetically modified veto cells and use of same in immunotherapy
CN110199017A (zh) 2017-01-20 2019-09-03 国立大学法人京都大学 CD8α+β+细胞毒性T细胞的制备方法
TWI832820B (zh) 2017-07-21 2024-02-21 美商伯克利之光生命科技公司 抗原呈現合成表面、共價功能化表面、經活化之t細胞及其用途
CA3094375A1 (en) 2018-03-28 2019-10-03 Board Of Regents, The University Of Texas System Use of histone modifiers to reprogram effector t cells
US11993766B2 (en) 2018-09-21 2024-05-28 Bruker Cellular Analysis, Inc. Functionalized well plate, methods of preparation and use thereof
WO2020069377A1 (en) * 2018-09-27 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of using lysine deacetylase (kdac) inhibition to generate antigen specific memory t cell responses for durable immunotherapy
KR20210078526A (ko) 2018-10-18 2021-06-28 버클리 라잇츠, 인크. 원 항원 제시 합성 표면, 활성화된 t 세포, 및 이들의 용도
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
ATE476496T1 (de) 1996-03-04 2010-08-15 Calyx Bio Ventures Inc Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
US20010031253A1 (en) 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
ES2292619T3 (es) * 2000-09-15 2008-03-16 Ortho-Mcneil Pharmaceutical, Inc. Composiciones y metodos para inducir respuestas citologicas especificas de la celula t.
WO2003057171A2 (en) * 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
DK1531850T3 (da) * 2002-06-07 2012-06-04 Zymogenetics Inc Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
AU2003275767A1 (en) * 2002-11-07 2004-06-07 Johnson & Johnson Research Pty Limited A means of producing and utilising a population of disease specific cytotoxic T-lymphocytes
KR101331746B1 (ko) * 2003-08-22 2013-11-20 다카라 바이오 가부시키가이샤 세포 상해성 림프구의 제조 방법
EP1814580B1 (en) 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
WO2006063301A1 (en) 2004-12-10 2006-06-15 Maxcyte, Inc. Genetically modified tumor cells as cancer vaccines
US9771331B2 (en) 2005-04-22 2017-09-26 The Johns Hopkins University Methods of identifying neuroprotective compounds for retinal ganglion cells
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
WO2009045308A2 (en) 2007-10-03 2009-04-09 Fred Hutchinson Cancer Research Center Enhanced generation of cytotoxic t-lymphocytes by il-21 mediated foxp3 suppression
EP3060059A4 (en) 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Polyclonal gamma delta t cells for immunotherapy
IL297773B2 (en) 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
BR112020005552A2 (pt) 2017-09-20 2020-10-27 Neximmune, Inc. composições de células compreendendo células t específicas de antígeno para terapia adotiva
CA3094375A1 (en) 2018-03-28 2019-10-03 Board Of Regents, The University Of Texas System Use of histone modifiers to reprogram effector t cells

Also Published As

Publication number Publication date
JP2008521406A (ja) 2008-06-26
US20190316088A1 (en) 2019-10-17
EP1814580A2 (en) 2007-08-08
US20100310533A1 (en) 2010-12-09
PL1814580T3 (pl) 2017-03-31
US11306289B2 (en) 2022-04-19
EP1814580B1 (en) 2016-08-10
ES2601896T3 (es) 2017-02-16
WO2006065495A3 (en) 2006-09-08
CY1122390T1 (el) 2020-07-31
US20220204933A1 (en) 2022-06-30
DK1814580T3 (en) 2016-12-12
WO2006065495A2 (en) 2006-06-22
PT1814580T (pt) 2016-11-11
US20150023938A1 (en) 2015-01-22
US20060269973A1 (en) 2006-11-30
LT1814580T (lt) 2016-12-12
CA2587136A1 (en) 2006-06-22
US9951310B2 (en) 2018-04-24

Similar Documents

Publication Publication Date Title
US20220204933A1 (en) Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
JP7698672B2 (ja) ガンマデルタｔ細胞の増幅、組成物およびその使用
US20230099491A1 (en) Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
Kuball et al. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2. 1-specific TCR
EP1812563B1 (en) Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
JP6230208B2 (ja) 樹状細胞／腫瘍細胞融合物および抗ｃｄ３／ｃｄ２８を使用する抗腫瘍免疫の刺激
ES2292619T3 (es) Composiciones y metodos para inducir respuestas citologicas especificas de la celula t.
Stevens et al. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
EP4461743A2 (en) T cell modification
US12577287B2 (en) T cell receptors and methods of use thereof
US20020131960A1 (en) Artificial antigen presenting cells and methods of use thereof
JP2020527036A (ja) 癌免疫療法用ｍｒ１制限ｔ細胞受容体
US8323965B2 (en) Identification of antigenic peptides from multiple myeloma cells
PL206976B1 (pl) Sposoby wytwarzania zawiesiny CD8⁺ do stosowania w leczeniu podmiotu z rakiem lub czerniakiem, sposób produkcji nie występującej naturalnie komórki i nie występująca naturalnie linia komórkowa
KR20240023426A (ko) 항원-특이적 t 세포를 생산하는 방법
CN102112491A (zh) 抗-cd8抗体阻断细胞毒素效应物的引发并导致调节性cd8+t细胞的产生
EP4253410A1 (en) Ras mutant epitope peptide and t cell receptor recognizing ras mutant
HK40117446A (en) T cell modification
Piapi Characterisation of CD3-enhanced gene-modified CD4+ T cells for cancer immunotherapy